US 12,459,993 B2
Anti-alpha-synuclein antibodies and uses thereof
Johnny Eugene Croy, Indianapolis, IN (US); Mansuo Lu Hayashi, Indianapolis, IN (US); Jirong Lu, Indianapolis, IN (US); Bo Ma, Indianapolis, IN (US); and Ying Tang, Indianapolis, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Appl. No. 17/413,771
Filed by Eli Lilly and Company, Indianapolis, IN (US)
PCT Filed Dec. 9, 2019, PCT No. PCT/US2019/065134
§ 371(c)(1), (2) Date Jun. 14, 2021,
PCT Pub. No. WO2020/123330, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/779,505, filed on Dec. 14, 2018.
Prior Publication US 2022/0048982 A1, Feb. 17, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 25 Claims
OG exemplary drawing
 
1. An anti-alpha-synuclein antibody comprising a heavy chain (HC) and a light chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and the LC comprises a light chain variable region (LCVR), and wherein the HCVR comprises a HCDR1, HCDR2, and HCDR3, and the LCVR comprises a LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of the HCDR1 comprises SEQ ID NO:1, the amino acid sequence of the HCDR2 comprises SEQ ID NO: 2, the amino acid sequence of the HCDR3 comprises SEQ ID NO: 3, the amino acid sequence of the LCDR1 comprises SEQ ID NO: 4, the amino acid sequence of the LCDR2 comprises SEQ ID NO: 5, and the amino acid sequence of the LCDR3 comprises SEQ ID NO: 6, and wherein Xaa at position 16 of SEQ ID NO: 2 is lysine, Xaa at position 5 of SEQ ID NO: 4 is serine, and Xaa at position 5 of SEQ ID NO: 5 is asparagine, or wherein Xaa at position 16 of SEQ ID NO: 2 is glutamine, Xaa at position 5 of SEQ ID NO: 4 is aspartic acid, and Xaa at position 5 of SEQ ID NO: 5 is aspartic acid.